Oncopeptides raises SEK 100 million for glioblastoma program
Oncopeptides has raised SEK 100 million before costs in a directed share issue to Swedish and international institutional investors. The money will fund the next clinical development phase of its glioblastoma program.
October 13, 2026
The company issued 50 million new ordinary shares at SEK 2.00 each, a discount of about 13.9 percent to Tuesday’s closing price. Its largest shareholder, HealthCap VIII, invested SEK 10 million. The issue dilutes existing shareholders by about 11.6 percent.
The proceeds will pay for the manufacturing (CMC) work needed before the next clinical phase, the preparations for starting that study, and the study itself. The raise follows data announced on 9 October showing that the company’s peptide-drug conjugate crossed the blood-brain barrier in the first patients in an ongoing study.
Oncopeptides drug crosses blood-brain barrier in first patients
Oncopeptides’ peptide drug conjugate crossed the blood-brain barrier in the first three patients treated in a glioblastoma study at Oslo University Hospital. Drug concentrations in the tumors matched preclinical models.
Oncopeptides also sells the multiple myeloma drug Pepaxti, whose net sales grew 74 percent to SEK 56.5 million in the first half of 2026. The company had cash of SEK 117 million at the end of September and still aims for positive cash flow during 2027.
Updated: October 14, 2026, 10:31 am
Published: October 13, 2026
